GFM
AQST icon

GF Fund Management’s Aquestive Therapeutics AQST Stock Holding History

GF Fund Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Sell
2,583
-144
-5% -$606 ﹤0.01% 531
2026
Q1 		$11.3K Buy
2,727
+330
+14% +$1.34K ﹤0.01% 551
2025
Q4 		$15.5K Sell
2,397
-206
-8% -$1.28K ﹤0.01% 534
2025
Q3 		$14.6K Buy
2,603
+341
+15% +$1.47K ﹤0.01% 523
2025
Q2 		$7.49K Hold
2,262
– – ﹤0.01% 598
2025
Q1 		$6.56K Buy
2,262
+348
+18% +$1.05K ﹤0.01% 606
2024
Q4 		$6.81K Buy
+1,914
New +$8.83K ﹤0.01% 591

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

GF Fund Management's AQST Position: Q2 2026 in Review

GF Fund Management reduced its Aquestive Therapeutics (AQST) stake by 5.3% in Q2 2026, selling an estimated $606 and leaving 2,583 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

GF Fund Management first reported a position in AQST in Q4 2024 and has held it in 7 quarters since. The position peaked at $15.5K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • GF Fund Management held 2,583 shares of Aquestive Therapeutics worth $10.7K as of Q2 2026.
  • GF Fund Management sold 144 Aquestive Therapeutics shares in Q2 2026, an estimated $606.
  • Aquestive Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #531 holding.
  • GF Fund Management first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Aquestive Therapeutics position peaked at $15.5K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.